N-[(3S,6S,12R,15S,19S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide | 23152-29-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 肽模拟物
• 英文名称: N-[(3S,6S,12R,15S,19S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide
• CAS: 23152-29-6
• 化学式: C₄₃H₄₉N₇O₁₀
• 分子量: 823.9
• InChiKey: FEPMHVLSLDOMQC-ZVGMWUGDSA-N

物化性质

• 熔点：
  240-242°
• 比旋光度：
  D20 -28° (c = 1 in ethanol)
• 溶解度：
  可溶于甲醇：5mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  60
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  225
• 氢给体数：
  4
• 氢受体数：
  11

制备方法与用途

生物活性

Virginiamycin S1 是一种环状十六肽抗生素，由弗氏链霉菌（Streptomyces virginiae）产生。它在氨酰基-tRNA 结合和肽键形成的水平上抑制细菌蛋白质合成，对多种革兰氏阳性菌显示出强大的杀菌活性。Virginiamycin S1 属于链阳性菌属家族中的 B 型化合物，并常与 A 型化合物 Virginiamycin M1 协同使用，以应对多药耐药性细菌感染。

文献信息

• Polymeric immunoglobulin receptor-mediated gene transfer
  申请人：CASE WESTERN RESERVE UNIVERSITY

  公开号：EP2025757A2

  公开（公告）日：2009-02-18

  We report the successful transfer of reporter genes into the airway epithelium in vivo following the injection of a targeting complex consisting of the Fab portion of immunoglobulin G directed against the rat polymeric immunoglobulin receptor conjugated to poly (L-lysine), and noncovalently bound to plasmid DNA. This technique specifically delivered the transgene to the liver and lung, tissues in which this receptor is expressed.

  我们报告了通过注射一种靶向复合物成功地将报告基因转入气道上皮细胞的情况。该复合物由针对大鼠聚合免疫球蛋白受体的免疫球蛋白 G 的 Fab 部分与聚（L-赖氨酸）结合而成，并与质粒 DNA 非共价结合。这种技术能将转基因特异性地输送到肝脏和肺部，而肝脏和肺部正是表达这种受体的组织。
• BIFUNCTIONAL MOLECULES FOR DELIVERY OF THERAPEUTICS
  申请人：Case Western Reserve University

  公开号：EP1165597A1

  公开（公告）日：2002-01-02
• EP1165597A4
  申请人：——

  公开号：EP1165597A4

  公开（公告）日：2003-06-11
• A METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY
  申请人：The University Of Western Australia

  公开号：EP3607084A1

  公开（公告）日：2020-02-12
• METHOD FOR TESTING ANTIMICROBIAL SUSCEPTIBILITY
  申请人：The University of Western Australia

  公开号：US20210292807A1

  公开（公告）日：2021-09-23

  The present invention relates to methods for the qualitative and quantitative determination of the susceptibility of microbial organisms such as bacteria to antimicrobial agents such as antibiotics. For example, the present invention provides a method of determining the susceptibility of a unicellular or multicellular microorganism to an antimicrobial agent by acoustic flow cytometry. The method comprising exposing cells of the microorganism to at least one antimicrobial agent, wherein said cells of the microorganism are in and/or derived from a sample obtained from a subject having or suspected of having an infection with said microorganism; measuring effect of said at least one antimicrobial agent on cellular morphology of said cells of the microorganism by acoustic flow cytometry; and determining susceptibility of the microorganism to the at least one antimicrobial agent from the acoustic flow cytometry data output.